Aligos Therapeutics, Inc.
ALGSDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
ALGS Earnings Report
EPS Est: $-1.40 | FQ end 2026-06
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How ALGS's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ALG-000184 | Phase 2 | Chronic Hepatitis B Infection | - | - |
ALG-055009 | Phase 2 | NASH | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Aligos Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Aligos Therapeutics, Inc.'s (ALGS) pipeline across Phase 2. Its lead program is ALG-000184 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Aligos Therapeutics, Inc.'s next FDA catalyst?→
Aligos Therapeutics, Inc.'s (ALGS) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ALGS biotech catalysts?→
Add ALGS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Aligos Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.